Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
Sunitinib may leads to lower serious adverse events (Grade 3 or 4) compared with IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted… (low certainty).
Temsirolimus may leads to lower serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent versus classic immunotherapy) (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with atezolizumab (targeted therapy versus immunotherapy) (moderate certainty).
Bevacizumab + IFN probably leads to higher serious adverse events (Grade 3 or 4) compared with IFN (+ placebo) (targeted agent + classic immunotherapy versus… (moderate certainty).
Temsirolimus + IFN‐α may leads to higher serious adverse events (Grade 3 or 4) compared with IFN‐α (targeted agent + classic immunotherapy versus classic… (low certainty).
Temsirolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted… (low certainty).
Everolimus + bevacizumab showed no clear difference in serious adverse events (Grade 3 or 4) compared with IFN α‐2a + bevacizumab (targeted agent + targeted agent versus… (low certainty).
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).
Pazopanib showed no clear difference in serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (low certainty).
Pazopanib leads to higher serious adverse events (Grade 3 or 4) compared with placebo (targeted agent versus placebo) (high certainty).
It is very uncertain whether peer support plus standard care changes adverse events: all cause – long term compared with standard care (very low certainty).
Bupropion XL showed no clear difference in discontinuation due to adverse events compared with placebo (low certainty).
Acupuncture showed no clear difference in adverse events related to acupuncture compared with sham control (low certainty).
It is very uncertain whether hospital‐in‐the‐home changes adverse events: hospital readmission; compared with hospital admission (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.